- Home
- HNVR vs MCRB Comparison
HNVR vs MCRB Comparison
Compare HNVR & MCRB Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- HNVR
- MCRB
- Stock Information
- Founded
- HNVR 2008
- MCRB 2010
- Country
- HNVR United States
- MCRB United States
- Employees
- HNVR N/A
- MCRB N/A
- Industry
- HNVR Commercial Banks
- MCRB Biotechnology: Pharmaceutical Preparations
- Sector
- HNVR Finance
- MCRB Health Care
- Exchange
- HNVR Nasdaq
- MCRB Nasdaq
- Market Cap
- HNVR 163.2M
- MCRB 141.9M
- IPO Year
- HNVR 2022
- MCRB 2015
- Fundamental
- Price
- HNVR $20.70
- MCRB $0.37
- Analyst Decision
- HNVR Buy
- MCRB Hold
- Analyst Count
- HNVR 1
- MCRB 5
- Target Price
- HNVR $22.00
- MCRB $4.00
- AVG Volume (30 Days)
- HNVR 15.1K
- MCRB 1.3M
- Earning Date
- HNVR 04-29-2025
- MCRB 05-07-2025
- Dividend Yield
- HNVR 1.95%
- MCRB N/A
- EPS Growth
- HNVR N/A
- MCRB N/A
- EPS
- HNVR 1.66
- MCRB 0.00
- Revenue
- HNVR $63,491,000.00
- MCRB N/A
- Revenue This Year
- HNVR N/A
- MCRB N/A
- Revenue Next Year
- HNVR $15.80
- MCRB N/A
- P/E Ratio
- HNVR $12.47
- MCRB $474.36
- Revenue Growth
- HNVR 5.04
- MCRB N/A
- 52 Week Low
- HNVR $13.62
- MCRB $0.46
- 52 Week High
- HNVR $27.14
- MCRB $1.53
- Technical
- Relative Strength Index (RSI)
- HNVR 46.68
- MCRB 28.34
- Support Level
- HNVR $18.60
- MCRB $0.36
- Resistance Level
- HNVR $21.05
- MCRB $0.67
- Average True Range (ATR)
- HNVR 1.22
- MCRB 0.07
- MACD
- HNVR 0.08
- MCRB -0.02
- Stochastic Oscillator
- HNVR 50.00
- MCRB 2.71
About HNVR Hanover Bancorp Inc.
Hanover Bancorp Inc is a United States-based banking company. It offers a full range of financial services and employs a complete suite of consumer and commercial banking products and services, including multi-family and commercial mortgages, residential loans, business loans, and lines of credit.
About MCRB Seres Therapeutics Inc.
Seres Therapeutics Inc is a microbiome therapeutics platform company operating in the United States. The company is engaged in developing biological drugs which are referred as ecobiotic microbiome therapeutics. The drugs discovered by the company are designed to restore health by repairing the function of a dysbiotic microbiome. The company focuses on implementing its microbiome therapeutics platform to develop ecobiotic microbiome therapeutics that treat dysbiosis in the colonic microbiome. SER-109, the company's product, is designed to prevent further recurrences of Clostridium difficile infection (CDI), a debilitating infection of the colon. In addition, the company is involved in developing SER-262, SER-287, and SER-401.